Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes
Rozemarijn M. Mattiesing(Amsterdam Neuroscience), Menno M. Schoonheim(Amsterdam Neuroscience), Eva Strijbis(Amsterdam University Medical Centers), Nicola De Stefano(University of Siena), Marco Battaglini(University of Siena), Iman Brouwer(Amsterdam Neuroscience), Frederik Barkhof(Netherlands Institute for Neuroscience), Hugo Vrenken(Amsterdam Neuroscience), Ronald A. van Schijndel(Amsterdam Neuroscience), Eline Kramer(Amsterdam Neuroscience), Giordano Gentile(University of Siena), Bernard M.J. Uitdehaag(Amsterdam UMC Location Vrije Universiteit Amsterdam)
Cited by 6
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
|Multiple Sclerosis Journal|2020|2.5k